Login to Your Account



Plexxikon Drug Shows Stunning 81 Percent Response in Melanoma

By Donna Young


Friday, August 27, 2010
In a space that's given many drug developers grief, Plexxikon Inc. had reason to be overjoyed this week, reporting a stunning 81 percent of metastatic melanoma patients with the BRAF V600E mutation had tumor shrinkage of at least 30 percent after receiving twice-daily dosages of PLX4032 (RG7204), a highly selective kinase inhibitor. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription